Type 2 Diabetes – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 2 Diabetes Market Outlook

Thelansis’s “Type 2 Diabetes Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Type 2 Diabetes treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Type 2 Diabetes Overview

Type 2 diabetes is a chronic and progressive metabolic disorder, typically irreversible, characterized by impaired metabolism of carbohydrates, fats, and proteins due to insufficient or ineffective use of the hormone insulin. Three core pathophysiological processes contribute to the development of type 2 diabetes: insulin resistance, defective insulin secretion, and excessive hepatic glucose production. This results in hyperglycemia, prompting increased insulin production, followed by a decline in the function and mass of pancreatic beta cells, ultimately leading to diabetes. In the majority of diabetic and prediabetic individuals, a high body mass index (BMI > 30) is a crucial predisposing factor for the onset of type 2 diabetes. There is a close association between the prevalence of insulin resistance and obesity. Vascular inflammation arising from hyperglycemia plays a pivotal role in the emergence of complications during late-stage diabetes, affecting both macro- and microvasculature and contributing to conditions such as retinopathy, neuropathy, nephropathy, and cardiovascular disease. Women, especially those with obesity, carry a more significant risk factor burden at the time of their type 2 diabetes diagnosis, with psychosocial stress potentially playing a more prominent role in diabetes risk for women. Additionally, pregnancies can unveil pre-existing metabolic abnormalities, leading to the diagnosis of gestational diabetes, a significant risk factor for progressing to type 2 diabetes in women. Gender differences exist in the context of type 2 diabetes and other cardiovascular risk factors, affecting comorbidities, the manifestation of complications, and the initiation and adherence to therapy. Women diagnosed with type 2 diabetes exhibit a greater relative risk of cardiovascular disease (CVD) and mortality compared to men. While the prevalence of type 2 diabetes mellitus is increasing in both sexes, men are typically diagnosed at a younger age and with lower body fat mass than women.

• In the USA, the prevalence rate of type 2 diabetes varies from 8.5% to 11.8% of the population, with approximately 78% of the prevalent population receiving treatment.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: